Premium
A meta‐analysis of the association between NQO1 C609T variation and acute myeloid leukemia risk
Author(s) -
Li Cuiping,
Liu Yun,
Wei Shujiao,
Zhou Yang
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24924
Subject(s) - medicine , meta analysis , subgroup analysis , myeloid leukemia , oncology , acute myeloblastic leukemia , publication bias , leukemia
Quinone oxidoreductase (NQO1) C609T polymorphisms have been implicated in acute myeloblastic leukemia (AML) risk, but previously published studies are inconsistent and recent meta‐analyses have not been adequate. To derive a more precise estimation of the relationship, a meta‐analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. The quality of studies was evaluated by using the Newcastle–Ottawa Scale (NOS). Crude ORs with 95% CIs were used to assess the strength of association between the NQO1 C609T polymorphisms and AML risk. A total of 14 studies including 2,245 cases and 3,310 controls were involved in this meta‐analysis. Overall, significantly elevated AML risk was associated with NQO1 C609T variant genotypes when all studies were pooled into the meta‐analysis (TT vs. CC: OR = 1.44, 95% CI = 1.15–1.81; dominant model: OR = 1.35, 95% CI = 1.09–1.68). In the subgroup analysis by ethnicity, significantly increased risks were found for Asians (OR = 1.47, 95% CI = 1.13–1.93, P = 0.005, I 2 = 48.4%, P = 0.071 for heterogeneity). When stratified by studies of adults or children, statistically significantly elevated risks were found among adults (OR = 1.37, 95% CI = 1.06–1.76, P = 0.017, I 2 = 42.2%, P = 0.097 for heterogeneity). The accumulated evidence indicates that NQO1 C609T seems to confer a risk factor for AML among Asians and adults. Significant between‐study heterogeneity was observed, thus more studies based on larger case‐control population are required to further evaluate the role of NQO1 C609T polymorphism in AML. Pediatr Blood Cancer 2014;61:771–777. © 2014 Wiley Periodicals, Inc.